In two Phase 1 trials that included 81 oncology patients, bardoxolone methyl reduced serum creatinine levels, with a corresponding improvement in estimated glomerular filtration rate (eGFR).
Also, in these Phase 1 trials, bardoxolone methyl reduced serum creatinine levels, with a corresponding improvement in estimated glomerular filtration rate (eGFR). In two Phase 1 trials that included 81 oncology patients, the following were demonstrated.
In two Phase 1 trials that included 81 oncology patients, the following were demonstrated. Also, in these Phase 1 trials, bardoxolone methyl reduced serum creatinine levels, with a corresponding improvement in estimated glomerular filtration rate (eGFR).
In two Phase 1 trials that included 81 oncology patients, the following were demonstrated. Also, in these Phase 1 trials, bardoxolone methyl reduced serum creatinine levels, with a corresponding improvement in estimated glomerular filtration rate (eGFR).